Zydus Lifesciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Zydus Lifesciences Ltd reported a 7.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.5%.
• Its expenses for the quarter were down by 6.2% QoQ and up 11.8% YoY.
• The net profit decreased 18.6% QoQ and increased 34.6% YoY.
• The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 12.51 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and marketing of a wide range of healthcare products. The company's portfolio includes generic drugs, biosimilars, and novel biologics, catering to various therapeutic segments. Zydus Lifesciences has established a significant presence globally, exporting its products to numerous countries. The company is known for its emphasis on research and development, consistently working to bring innovative healthcare solutions to the market. As of the latest available data, there are no specific recent major developments mentioned.

Revenue

During the second quarter of the fiscal year 2026 (Q2FY26), Zydus Lifesciences Ltd. reported a total income of ₹6232.20 crores. This represents a decline of 7.4% compared to the previous quarter (Q1FY26), where the total income stood at ₹6728.60 crores. However, when compared to the same quarter in the previous year (Q2FY25), there is a year-over-year increase of 17.5%, as the total income was ₹5305.20 crores then. This suggests that despite the quarterly decline, the company has experienced significant growth over the year.

Profitability

In Q2FY26, the company recorded a profit before tax of ₹1687.40 crores, which is a decline of 12.1% from Q1FY26's profit before tax of ₹1920.60 crores. Year-over-year, there is a notable growth of 32.8% from Q2FY25, where the profit before tax was ₹1270.90 crores. The profit after tax for Q2FY26 was ₹1238.60 crores, a decrease of 18.6% from the previous quarter. However, compared to Q2FY25, there is a substantial increase of 34.6%, with the previous year's figure being ₹920.20 crores. This reinforces the yearly growth trend despite the quarterly decrease.

Operating Metrics

The total expenses for Q2FY26 amounted to ₹4510.60 crores, showing a reduction of 6.2% from Q1FY26, where expenses were ₹4808.00 crores. Comparing year-over-year, there is an increase of 11.8% from Q2FY25, when expenses were ₹4034.30 crores. The earnings per share (EPS) in Q2FY26 were ₹12.51, down from ₹14.58 in Q1FY26, marking a 14.2% decrease quarter-over-quarter. However, there is a 38.1% year-over-year increase from Q2FY25's EPS of ₹9.06. This indicates that while there was a decline in the quarter, the company has achieved significant growth on an annual basis.